Partnering off the beaten path: How are early-stage biotech collaboration dynamics changing?

Edition

Partnering off the beaten path: How are early-stage biotech collaboration dynamics changing?

As the biopharma industry and individual biotech companies themselves mature, partnering options are also expanding. At the early stages of the drug development life cycle, companies now have options outside of the historical biotech-pharma pair-up.

What other partnership options do biotech companies use today, from translation of academic research to industry and co-development?  How do biotech companies identify the right ecosystem and partners? What are the partnering and transaction strategies of small companies in a competitive environment? Are some therapeutic areas more likely to lead to inter-biotech collaborations?

 

Moderator: Kathrin Ballesteros, Venture Partner, NLC – The European Healthtech Venture Builder

Kristin Thompson

VP, Chief Business Officer
France
eureKARE

Ajan Reginald

Chief Executive Officer // Managing Director
United Kingdom
Roquefort Therapeutics PLC // Celixir Ltd

Vincent Brichard

Venture Partner
The Netherlands
EQT Life Sciences

Anette Sommer

Senior Director Emerging Science Lead Oncology Europe
Germany
Pfizer

Zuzanna Brzosko

Senior Director, Corporate Strategy & External Innovation
United Kingdom
Eli Lilly and Company
  • No products in the cart.